Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of PBI-4547 in Healthy Subjects

Trial Profile

A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of PBI-4547 in Healthy Subjects

Status: Suspended
Phase of Trial: Phase I

Latest Information Update: 19 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PBI 4547 (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Adverse reactions; First in man
  • Sponsors Liminal BioSciences
  • Most Recent Events

    • 17 Nov 2019 Status changed from recruiting to suspended, according to a ProMetic Biosciences media release.
    • 11 Nov 2019 According to a ProMetic Biosciences media release, this trial has been suspended while the company is reviewing the Pharmacokinetic data from the first 3 cohorts. No safety issues or severe adverse effects have been observed.
    • 18 Oct 2019 According to a ProMetic Biosciences media release, presentation of the study will be given at H.C. Wainwright & Co. 3rd Annual NASH Investor Conference at 16:20 ET on Monday, October 21, 2019 in New York, USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top